Jared M. Baeten, M.D., Ph.D., is vice chair and professor in the Department of Global Health at the University of Washington, where he is also professor in the departments of Medicine and Epidemiology. His research focuses on the prevention of HIV and other sexually transmitted diseases, which he pursues through clinical trials of novel prevention interventions, epidemiologic studies of risk factors for HIV transmission, and behavioral, translational, and implementation science research aimed at optimizing prevention delivery. In December 2016 he was named co-principal investigator of the U.S. National Institutes of Health-funded Microbicide Trials Network (MTN). Dr. Baeten was protocol chair of ASPIRE (MTN-020), a multinational phase III trial of the dapivirine vaginal ring for HIV prevention in women conducted through the MTN. Both ASPIRE and its sister study, The Ring Study, found the dapivirine ring safe and effective in helping to protect against HIV, a first for a product developed specifically for women. Dr. Baeten is now leading the HOPE study (MTN-025), an open-label extension trial in which former ASPIRE participants have the opportunity to use the dapivirine ring.
Previously, Dr. Baeten led the Partners PrEP Study, which demonstrated daily use of the antiretroviral drug Truvada® – an approach called pre-exposure prophylaxis, or PrEP – highly effective in protecting against HIV among serodiscordant heterosexual couples. Based in large part on these results, the U.S, Food and Drug Administration approved the use of Truvada as PrEP in 2012. Since then, a number of other countries have approved Truvada for use in HIV prevention and the World Health Organization (WHO) has recommended oral PrEP for all persons at substantial HIV risk.
Outside of the MTN, Dr. Baeten is overseeing implementation studies to deliver antiretroviral treatment and PrEP for HIV prevention; epidemiology and clinical studies exploring use of hormonal contraception as an HIV risk factor, including as a member of the leadership committee for the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study; and collaborative studies of immunologic and virologic factors that influence HIV transmission.
When not conducting research, Dr. Baeten is an attending physician in infectious diseases at Harborview Medical Center in Seattle. He earned his medical degree and a Ph.D. in epidemiology from the University of Washington, completed residency training in primary care internal medicine at Massachusetts General Hospital in Boston and returned to the University of Washington to complete a fellowship in infectious diseases. In 2014, Dr. Baeten was named a fellow in the Infectious Diseases Society of America. He has authored or co-authored more than 200 peer-reviewed manuscripts.
# # #